Advances in medical diagnosis, treatment, and care (AMDTC) book series,
Год журнала:
2024,
Номер
unknown, С. 419 - 472
Опубликована: Авг. 28, 2024
Monoclonal
antibodies
(mAbs)
can
significantly
improve
patient
outcomes
in
cancer
treatment
while
reducing
related
side
effects,
offering
a
targeted
therapy
alternative
to
traditional
regimens.
This
chapter
describes
the
development,
mechanisms,
and
applications
of
mAb
therapies
as
critical
components
immunotherapy.
The
covers
history
progression
use
mAbs
therapy,
their
multiple
mechanisms—such
immune
checkpoint
inhibitors,
acumen
for
antigens
antibody—drug
conjugates—and
newest
developments
this
area.
Moreover,
reviews
relevant
case
studies
trial
data
compare
impact
these
agents
on
various
malignancies.
concludes
with
summary
current
challenges—developed
resistance,
one
hand—and
toxic
e.g.,
cytokine
release
syndrome
neurotoxicity,
other—and
prospective
avenues
field.
Journal of drug targeting,
Год журнала:
2025,
Номер
unknown, С. 1 - 23
Опубликована: Янв. 4, 2025
Colorectal
cancer
(CRC)
continues
to
be
a
major
worldwide
health
issue,
with
elevated
death
rates
linked
late
stages
of
the
illness.
Immunotherapy
has
made
significant
progress
in
developing
effective
techniques
improve
immune
system's
capacity
identify
and
eradicate
cancerous
cells.
This
study
examines
most
recent
advancements
CAR-T
cell
treatment
exosome-based
immunotherapy
for
CRC.
therapy,
although
treating
blood
cancers,
encounters
obstacles
when
used
against
solid
tumors
such
as
These
include
presence
an
immunosuppressive
tumor
microenvironment
scarcity
tumor-specific
antigens.
Nevertheless,
novel
strategies
like
dual-receptor
cells
combination
therapy
involving
cytokines
have
demonstrated
promise
surmounting
these
obstacles.
Exosome-based
is
promising
approach
targeted
delivery
therapeutic
drugs
cells,
high
specificity
minimal
off-target
effects.
However,
there
are
still
overcome
field,
resistance
treatment,
adverse
effects
associated
system,
necessity
more
individualized
methods.
The
current
research
focused
on
enhancing
therapies,
results
patients,
ultimately
incorporating
innovative
immunotherapeutic
approaches
into
standard
protocols
Immune
checkpoint
inhibitors
(ICIs)
have
dramatically
transformed
the
treatment
landscape
for
various
malignancies,
achieving
notable
clinical
outcomes
across
a
wide
range
of
indications.
Despite
these
advances,
resistance
to
immune
blockade
(ICB)
remains
critical
challenge,
characterized
by
variable
response
rates
and
non-durable
benefits.
However,
growing
research
into
complex
intrinsic
extrinsic
characteristics
tumors
has
advanced
our
understanding
mechanisms
behind
ICI
resistance,
potentially
improving
outcomes.
Additionally,
robust
predictive
biomarkers
are
crucial
optimizing
patient
selection
maximizing
efficacy
ICBs.
Recent
studies
emphasized
that
multiple
rational
combination
strategies
can
overcome
enhance
susceptibility
ICIs.
These
findings
not
only
deepen
tumor
biology
but
also
reveal
unique
action
sensitizing
agents,
extending
benefits
in
cancer
immunotherapy.
In
this
review,
we
will
explore
underlying
ICIs,
discuss
significance
microenvironment
(TIME)
biomarkers,
analyze
current
outline
alternative
effectiveness
including
personalized
Frontiers in Oncology,
Год журнала:
2025,
Номер
15
Опубликована: Март 26, 2025
Background
Bevacizumab
is
a
primary
focus
in
the
clinical
application
and
research
of
metastatic
colorectal
cancer
(mCRC)
patients.
This
study
aims
to
analyze
publications
on
bevacizumab
CRC
explore
identify
trends
frontiers
this
field.
Methods
We
collected
4,164
articles
from
Web
Science
Core
Collection
(WoSCC).
CiteSpace,
VOSviewer,
R-bibliometrix,
Microsoft
Excel
were
utilized
for
analysis
visualization.
Results
The
United
States,
Japan,
China
are
leading
countries
National
Cancer
Institute
University
Pisa
share
top
position
highest
number
publications.
Personalized
therapy,
innovative
combination
treatments,
mechanisms
resistance,
new
drug
development
enduring
focal
points
future
directions.
Conclusions
provides
first
bibliometric
CRC,
revealing
current
status
directions
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Дек. 15, 2024
Abstract
This
phase
2/3
trial
(NCT04856787)
assessed
the
efficacy
and
safety
of
SHR-1701,
a
bifunctional
protein
targeting
PD-L1
TGF-β,
in
combination
with
BP102
(a
bevacizumab
biosimilar)
XELOX
(capecitabine
plus
oxaliplatin)
as
first-line
treatment
for
unresectable
metastatic
colorectal
cancer
(mCRC).
In
this
2
study,
total
62
patients
untreated,
histologically
confirmed
adenocarcinoma
no
prior
systemic
therapy
disease
were
enrolled.
Patients
received
SHR-1701
(30
mg/kg),
(7.5
oxaliplatin
(130
mg/m
)
intravenously
on
day
1,
along
oral
capecitabine
(1
g/m
twice
daily)
days
1–14
21-day
cycles.
Up
to
eight
induction
cycles
administered,
followed
by
maintenance
responders
or
those
stable
disease.
The
primary
endpoints
objective
response
rate
(ORR)
per
RECIST
v1.1.
achieved
an
ORR
59.7%
control
(DCR)
83.9%.
Median
progression-free
survival
(PFS)
was
10.3
months
(95%
CI:
8.3–13.7),
6-
12-month
PFS
rates
77.2%
41.3%,
respectively.
estimated
overall
(OS)
67.7%.
Grade
≥3
treatment-related
adverse
events
(TRAEs)
reported
patients,
anemia
neutropenia
(8.1%
each)
being
most
common.
Retrospective
DNA
sequencing
revealed
that
high
tumor
mutational
burden,
neo-antigens,
SBS15
enrichment
correlated
better
responses.
Elevated
baseline
lactate
dehydrogenase
linked
shorter
PFS.
combined
demonstrated
manageable
profile
potent
antitumor
activity
mCRC.
IUBMB Life,
Год журнала:
2024,
Номер
76(12), С. 1050 - 1057
Опубликована: Авг. 12, 2024
This
systematic
literature
review
and
meta-analysis
provide
an
overview
of
the
critical
role
gut
microbiota
in
modulating
efficacy
immunotherapy
for
colorectal
cancer.
Gut
microbes
influence
host
immune
responses
through
multiple
mechanisms
including
modulation
cell
activity,
metabolite
action,
tolerance.
The
ability
specific
to
improve
checkpoint
inhibitors
has
been
linked
their
barrier
function,
modulate
produce
key
immunomodulatory
metabolites
such
as
short-chain
fatty
acids.
In
addition,
composition
diversity
are
strongly
associated
with
immunotherapies,
demonstrating
potential
therapeutic
response
by
modifying
microbiota.
paper
also
discusses
prospect
manipulating
strategies
fecal
microbial
transplantation,
probiotic
supplementation,
dietary
modifications
optimize
immunotherapy.
Cancers,
Год журнала:
2024,
Номер
16(22), С. 3870 - 3870
Опубликована: Ноя. 19, 2024
Metastatic
colorectal
cancer
is
a
leading
cause
of
cancer-related
death
across
the
world.
The
treatment
paradigm
has
shifted
away
from
systemic
chemotherapy
alone
to
include
targeted
therapy
and
immunotherapy.
past
two
decades
have
been
characterized
by
increased
investigation
into
molecular
profiling
cancer.
These
profiles
help
physicians
better
understand
biology
among
patients
with
metastatic
disease.
Additionally,
improved
data
on
genetic
pathways
allow
for
specific
therapies
be
at
underlying
profile.
Investigation
EGFR,
VEGF,
HER2,
other
pathways,
as
well
deficient
mismatch
repair,
led
development
multiple
that
are
now
utilized
in
National
Comprehensive
Cancer
Network
guidelines
colon
rectal
While
these
new
contributed
survival
cancer,
long-term
remains
poor.
Additional
resistance
necessary.
New
under
being
tested
preclinical
clinical
settings.
aim
this
review
provide
comprehensive
evaluation
profiling,
currently
available
therapies,
ongoing
obstacles
field
